Urtoxazumab (1.0 mg/kg) vs placebo
Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).
1 finding from 1 review
- Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes onlyRR 0.95 [0.79, 1.13]1 study · 74 participantsLow